Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV - Seite 2

The third interview is with Simon Morriss, CEO of Genetic Technologies. Genetic Technologies is executing a B2B commercialization strategy for its flagship geneType Multi-Risk test covering breast cancer, colorectal cancer, prostate cancer, ovarian cancer, coronary artery disease and Type-2 diabetes, a first-in-class test that can predict a person's risk in up to 70% of annual mortalities and morbidities before onset. Recently, the Company's assessments for Pancreatic Cancer, Melanoma, and Atrial Fibrillation, were authorized for sale in Australia by National Association of Testing Authority (NATA). Genetic Technologies also signed a precision medicine pilot with Gold Coast Private Hospital (GCPH), a member of Healthscope - Australia's largest private hospital network. Separately, the Company also recently announced a Medical Research Future Fund (MRFF) Genomics Health Futures Mission Grant has been awarded to a group of renowned national and international research and charity organizations. The grant will provide funding for the CASSOWARY Trial: a randomized controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice. GTG is the National Research Partner for trial.

About Knightscope, Inc.

Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope's long-term ambition is to make the United States of America the safest country in the world. Learn more about us at www.knightscope.com.

About Soligenix, Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203).